Introduction
The p53 tumor suppressor gene is mutated in more than 50% of human cancer (Lane and Benchimol, 1990; Hollstein et al., 1991; Levine et al., 1991) . Since inactivation or down-regulation of p53 can occur through overexpression of certain cellular proteins (i.e., MDM2, (Haupt et al., 1997; Kubbutat et al., 1997) and viral proteins (i.e. E6 of human papilloma virus, see Scheffner et al., 1990) , the frequency of p53 inactivation in human cancer is expected to be significantly higher than that estimated from the p53 mutation alone. The tumor suppressor function of p53 was illustrated by the observation that mice lacking functional p53 (p53 7/7 mice) develop various types of tumors early in life (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . Latency for spontaneous tumors in heterozygous (p53+/7) mice is longer than in p53 7/7 mice. However, p53+/7 mice eventually develop tumors, and these tumors generally show loss or mutation of the remaining p53 allele (Harvey et al., 1993a,b) . p53 possesses multiple functions (for reviews, Ko and Prives, 1996; Mowat, 1998) . It binds to specific DNA sequences, and acts as a transcription factor for a number of genes. It also binds non-specifically to DNA and RNA, and promotes annealing of single stranded DNA and RNA. In addition, p53 has been shown to localize to centrosomes (Blair Zajdel and Blair, 1988; Brown et al., 1994; Morris et al., 2000; Ciciarello et al., 2001; Tarapore et al., 2001b) , although the functional significance of its centrosomal association remains unclear.
A number of experimental and clinical studies have shown a strong correlation between loss or mutational inactivation of p53 and chromosome instability (ploidy changes). In mice, it is clearly demonstrated by cytogenetic analysis of cultured fibroblasts as well as tissues directly derived from p53 7/7 mice, exhibiting a high degree of aneuploidy (Harvey et al., 1993a,b; Purdie et al., 1994; Bouffler et al., 1995; Donehower et al., 1995; Fukasawa et al., 1997) . Studies of various human tumors have also revealed a strong correlation between mutated or deleted p53 and emergence of aneuploidy (there are over 400 references on this topic. For a review, see Hainaut and Hollstein, 2000) . Since loss and/or gain of chromosomes simultaneously introduces multiple genetic lesions to cells, chromosome instability is considered to be a formidable force promoting multi-step carcinogenesis. It has been shown that loss or mutation of p53 induces abnormal amplification of centrosomes, leading to an increased frequency of defective mitosis organized by multiple spindle poles, resulting in mis-segregation of chromosomes into daughter cells (Fukasawa et al., 1996) . This is at least one of the major mechanisms underlying chromosome instability associated with mutation of p53. In this review, we will discuss the molecular aspects of how loss or mutational inactivation of p53 leads to centrosome hyperamplification.
Loss of p53 and centrosome hyperamplification
Several years ago, through examination of embryonic fibroblasts derived from p53 7/7 mice (p53 7/7 MEFs), we reported that loss of p53 lead to abnormal amplification of centrosomes (or microtubule organizing centers -MTOCs) (Figure 1a ) (Fukasawa et al., 1996) . Although there are some differences from litter to litter, early passage p53 7/7 MEFs show abnormal centrosome profiles with 10 -20% of cells with single MTOC, 40 -50% of cells with two MTOCs, and 30 -50% of cells with more than two MTOCs (Figure 1b) . The presence of multiple MTOCs during interphase as well as multiple spindle poles during mitosis in p53
cells raises the question of whether all these MTOCs are duplicated centrosomes or fragmented pericentriolar material (PCM). Co-immunostaining of coldtreated and briefly extracted p53 7/7 cells with anti-gtubulin antibody (which detects PCMs) and anti-atubulin antibody (which detects centrioles) revealed that all of the hyperamplified MTOCs in p53
7/7 cells Figure 1 Centrosome hyperamplification in p53 7/7 cells. (a) p53 +/+ and p53 7/7 MEFs (passage 3) were immunostained for gtubulin, a major component of centrosomes (reviewed in Joshi, 1994) . p53 +/+ cells contain either one or two centrosomes, depending on before or after duplication. In contrast, many of the p53 7/7 cells contain an abnormal number (53) of centrosomes. (b) The g-tubulin-stained cells were statistically analysed for cells with unduplicated centrosomes (n=1), with duplicated centrosomes (n=2) and with hyperamplified centrosomes (n53). (c) To examine the presence of centrioles within the hyperamplified centrosomes, p53 7/7 MEFs were subjected to cold-treatment and brief extraction prior to fixation. This treatment destabilizes microtubules nucleated at centrosomes; hence centrioles can be microscopically visualized by immunostaining for a-tubulin, a major component of centrioles, at a high magnification. Cells were co-immunostained with anti-g-tubulin polyclonal and anti-a-tubulin monoclonal antibody, and counterstained with DAPI. Panel d shows the overlay of the images shown in panels a and b. Panels I-III are the magnified images of the area indicated as insets in panel b. The blue arrows point to single centrioles, while the white arrows point to paired centrioles. All the spots detected by anti-g-tubulin antibody contain either single or paired centrioles. Scale bar; 10 mm. . Indeed, when centrosomes of these multi-nucleated cells were examined, they all contained an abnormal number (53) of centrosomes. These observations indicate that loss of p53 leads to an increased frequency of cytokinesis failure, and this at least in part accounts for an abnormal number of centrosomes in p53 7/7 cells. This is consistent with the recent reports showing that loss of p53 results in up-regulation of aurora kinase (Meraldi et al., 2002 ; also see Prigent in this issue), which is responsible for the cytokinesis failure. However, the flow cytometric analysis of early passage p53 +/+ and p53 7/7 MEFs revealed that the majority of cells (497% of p53 +/+ cells and 490% of p53 7/7 cells) belong to the cell population with 2N/4N DNA content ( Figure 3b ). It should be noted that among p53 7/7 cells, some cells contain either more than 4N DNA content (but not to the level of genomedoubling) or less than 2N, likely reflecting gain and loss of chromosomes, respectively (indicated by open arrows). Since 30 -50% of p53 7/7 MEFs contain 3 centrosomes, the majority of cells with 53 centrosomes are in the 2N/4N cell population. Indeed, examination of p53 7/7 cells with 2N DNA content sorted by FACS showed that many of these cells contained 53 centrosomes. Because it is highly unlikely that cells that have failed to undergo cytokinesis will subsequently divide into cells with 2N DNA content, these results indicate that the regulation of centrosome duplication is abrogated in p53 7/7 cells, leading to multiple rounds of centrosome duplication in a single cell cycle, resulting in hyperamplified centrosomes. Thus, deregulation of the centrosome duplication cycle is likely the major route for cells to possess excess number of centrosomes in the absence of p53.
p53 controls both initiation of centrosome duplication and suppression of re-duplication There are two major regulatory mechanisms forced upon centrosome duplication (Figure 4) . One is to establish the correct timing of initiation of duplication, which ensures the coordination of initiation of centro- +/+ and p53 7/7 MEFs (passage 3) were stained with Giemsa, and examined under a microscope. There is a small increase in the number of cells with more than two nuclei in p53 7/7 MEFs (4 -5%) compared with p53 +/+ MEFs (*1% some and DNA duplication, and the other is to prevent re-duplication of centrosomes once they have duplicated. Knowing that the major route for centrosome hyperamplification in the p53-null background is via deregulated duplication of centrosomes, the question arises whether p53 controls initiation of centrosome duplication or suppression of re-duplication or both. To this end, early passage p53 +/+ and p53 7/7 MEFs were examined for the ability to coordinate the initiation of centrosome and DNA duplication by a time course study of serum-stimulated cells that had been synchronized by serum-starvation. In p53 +/+ MEFs, initiation of centrosome duplication is tightly coupled with initiation of DNA duplication. In contrast, in p53
MEFs, centrosomes initiate duplication early in G1 much before S phase entry (Tarapore et al., 2001a) . Thus, p53 is involved in the regulation of initiation of centrosome duplication. p53 +/+ and p53 7/7 MEFs were also examined for their ability to suppress reduplication of centrosomes by the assay originally described by Balczon et al. (1995) using CHO (Chinese Hamster Ovary) cells. In this assay, cells are treated with DNA synthesis inhibitors such as aphidicolin and hydroxyurea for 36 -72 h. In these cells, DNA synthesis is inhibited, while centrosomes continue to duplicate, resulting in generation of multiple copies of centrosomes. In the aphidicolin-treated p53 +/+ MEFs, no centrosome re-duplication was observed. In contrast, in the aphidicolin-treated p53 7/7 MEFs, centrosomes continued to re-duplicate, similar to that observed in CHO cells (Tarapore et al., 2001a) . Thus, re-duplication of centrosomes in this assay depends on the p53 status. This finding agrees with the fact that p53 is mutated in CHO cells (Hu et al., 1999; Lee et al., 1997; Moro et al., 1995) . We have examined several human cell lines with different p53 status, including IMR90 and HEL 299 (non-transformed embryonic lung fibroblasts, p53-positive) as well as SAOS-2 (osteosarcoma cell lines, p53-negative), and we found a perfect correlation between inactivation of p53 and ability to re-duplicate centrosomes (K Fukasawa, unpublished data). From these observations, it is clear that p53 is also involved in suppression of re-duplication of centrosomes.
Does p53 control centrosome duplication directly or indirectly?
Since p53 is also involved in DNA repair and checkpoint response to genotoxic as well as physiological stress (for reviews, see Ko and Prives, 1996; Mowat, 1998) , loss of p53 is expected to result in an increased frequency of genetic mutations. Thus, it is possible that loss of p53 leads to secondary mutations of other genes, whose products are the direct regulators of the centrosome duplication cycle. In this setting, loss of p53 indirectly induces centrosome hyperamplification. In contrast, p53 may be directly and actively involved in the regulation of centrosome duplication. If the former possibility is correct, re-introduction of wild-type p53 into p53 7/7 cells should not restore the centrosome duplication cycle, since the secondary mutation(s) continue to exist. On the other hand, if the latter possibility is correct, the centrosome duplication cycle of p53 7/7 cells should be restored by re-introduction of wild-type p53. When wild-type p53 was re-introduced at a physiological level into p53 7/7 MEFs, the centrosome profile was almost completely restored (Tarapore et al., 2001a) . This includes both coupling of initiation of centrosome and DNA duplication and suppression of re-duplication. Ouyang et al. (2001) have recently reported similar findings: transfection of wild-type p53 into human prostate cell lines (PC3 and DU145) resulted in significant lessening of centrosome abnormalities. Thus, p53 directly controls both initiation of centrosome duplication and suppression of re-duplication. In further support, introduction of either MDM2 (which promotes degradation of p53, see Haupt et al., 1997; Kubbutat et al., 1997) or a gain-of-function mutant Figure 4 Involvement of p53 in the two major regulatory mechanisms imposed on centrosome duplication. The centrosome duplication is under two major controls: (1) Establishment of the correct timing of initiation of centrosome duplication, which normally occurs at late G1. This in turn ensures the coordinated initiation of centrosome and DNA duplication. (2) Suppression of re-duplication of centrosomes within a single cell cycle. p53 is directly involved in both regulations p53 (which functionally inactivates wild-type p53 through sequestration) rapidly induces centrosome hyperamplification (Carroll et al., 1999; Murphy et al., 2000) . If centrosome hyperamplification is induced by secondary mutations, it should take a much longer time for cells with appropriate mutations and hyperamplified centrosomes to clonally expand in the culture enough to exhibit the changes in centrosome profile.
Effectors of p53 in the regulation of centrosome duplication
In somatic cells, a family of serine/threonine kinases known as CDKs controls the onset of the major cell cycle events such as DNA synthesis and mitosis (reviewed in Heichman and Roberts, 1994; Nurse, 1994; Sherr, 1994; Reed, 1997) . The activity of CDKs is regulated by their association with different cyclins, which are expressed at specific cell cycle stages. For example, expression of cyclin E, which associates with CDK2, occurs in late G1 (Dulic et al., 1992; Koff et al., 1992) . It has recently been shown that the activation of CDK2/cyclin E is also critical for the initiation of centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999; Tarapore et al., 2002) . Since CDK2-cyclin E is known to be a factor that triggers DNA synthesis (Ohtsubo and Roberts, 1993; van den Heuvel and Harlow, 1993) , the temporal activation of CDK2/cyclin E at late G1 is likely a key event that coordinates the initiation of centrosome and DNA duplication. Indeed, constitutive activation of CDK2/cyclin E in cells results in uncoupling of initiation of centrosome and DNA duplication (Mussman et al., 2000) . In these cells, centrosomes duplicate early in G1 much before S phase entry. The uncoupling of these two events most likely reflects the fact that initiation of centrosome duplication primarily depends on CDK2/cyclin E, while DNA synthesis can be triggered by CDK2/cyclin E only after other CDK2/cyclin-independent events necessary for DNA synthesis are completed. p21 Waf1/Cip1/Sdi1 (p21), a major target of p53's transactivation function, belongs to a family of proteins known as CDK inhibitors (reviewed in Harper and Elledge, 1996; Sherr and Roberts, 1999) . p21 specifically targets G 1 /S CDK/cyclin complexes, including CDK2/cyclin E. In normal cells, low level of p21 is constitutively present in a p53-dependent manner (Mussman et al., 2000) . This raises the possibility that the continual presence of p21 may guard against premature activation of CDK2/cyclin E, ensuring the coordinated initiation of centrosome and DNA duplication. In support of this possibility, in p21
MEFs, initiation of centrosome and DNA duplication is uncoupled (centrosomes initiate duplication early in G1 much before S phase entry) much like cells with constitutively active CDK2/cyclin E (Mussman et al., 2000; Tarapore et al., 2001a) . Moreover, ectopic expression of p21 at a physiological level in p21
MEFs restored the normal centrosome profile as well as the coupling of initiation of centrosome and DNA duplication (P Tarapore, unpublished observation).
The next obvious question is whether p21 plays a role in the p53-mediated regulation of centrosome duplication. When p21 was introduced into p53 7/7 cells at a physiological level, only partial restoration of the centrosome profile as well as coordination of centrosome and DNA duplication was observed (Tarapore et al., 2001a) . Considering that re-introduction of wild-type p53 into p53 7/7 cells results in nearly complete restoration of the centrosome duplication cycle, p53 controls centrosome duplication through multiple pathways, and one of which is mediated by p21 ( Figure 5 ).
Centrosomal association of p53 and regulation of centrosome duplication p53 has long been known to be present at centrosomes throughout the cell cycle (Blair Zajdel and Blair, 1988; Brown et al., 1994; Morris et al., 2000; Ciciarello et al., 2001; Tarapore et al., 2001b) . However, it had been unclear whether the centrosomal association of p53 had any physiological significance, especially in centrosome biology. To answer this question, we examined two 'hotspot' transactivation negative mutants of p53, R175H and R249S, for their effects on centrosome duplication in p53 7/7 cells. The reasons for choosing these particular mutants were (1) both are shown to be completely transactivation negative (Crook et al., 1994) , and (2) clinical studies show that tumors with a mutation at residue 175 are generally far more aggressive than those with mutation at 249 (Aas et al., 1996; Wang et al., 1998a,b; Liu et al., 2000) . These two mutants were stably transfected in p53 7/7 cells, and the transfectants were examined for possible changes in their centrosome profile. There was no restoration in the centrosome profile of R175H-transfectants, and rather interestingly expression of R175H exacerbated centrosome abnormality of p53 7/7 cells. In contrast, significant restoration was observed in the R249S-transfectants, both in coupling of centrosome and DNA duplication and suppression of re-duplication (Tarapore et al., 2001b) . Thus, p53 partly controls centrosome duplication in a transactivation-independent manner. Importantly, it was further found that there was a difference in the centrosome binding activity between R175H and R249S: R249S, similar to wild-type p53, can be detected at both unduplicated and duplicated centrosomes, while R175H cannot be detected at unduplicated centrosomes (Tarapore et al., 2001b) . These observations indirectly suggest that p53 regulates centrosome duplication through physical association with centrosomes ( Figure 5 ).
Centrosome binding activity of p53 is partly controlled by phosphorylation on Ser 315. When p53 mutants with a replacement of Ser 315 to alanine (S315A) and aspartic acid (S315D) were examined, it was found that S315D associated with both unduplicated and duplicated centrosomes similar to wild-type p53, while S315A associated only with duplicated centrosomes (Tarapore et al., 2001b) . At this point, a molecular mechanism of the regulation of centrosome duplication by centrosomal association of p53 is not known. Identification of the centrosomal protein(s) that directly associates with p53 will clearly shed light on answering this question, since it is possible that p53 may modulate the activity of certain centrosomal component(s) through direct physical interaction. In fact, such a case has been previously described for the p53's transactivation-independent function (Brown et al., 2000) .
Loss of p53, centrosome hyperamplification and human cancer
Many of the molecular studies of centrosome duplication in higher animal cells have been done using mouse cells partly because mouse primary cells are readily available and genetic manipulation is relatively easy in mouse cells compared with human cells. Studies using mouse cells clearly demonstrated that centrosome hyperamplification is induced by loss or inactivation of p53, which in turn leads to mitotic defects and chromosome instability. Similarly, in human tumors and in cultured human tumor cell lines, a number of studies have shown a strong correlation between p53 mutations and centrosome hyperamplification, including breast tumors (Carroll et al., 1999; Lingle et al., 2002) , squamous cell carcinomas of the head and neck (Carroll et al., 1999) , cerebral primitive neuroectodermal tumor cells (Weber et al., 1998) and prostate cancer cell lines (Ouyang et al., 2001) . However, it has also been shown that inactivation of p53 in human diploid cell lines does not lead to extensive centrosome hyperamplification, nor chromosome instability (Lengauer et al., 1997; Bunz et al., 2002) . Apparently, in human cells, numeral integrity of centrosomes and chromosome stability are more strictly guarded than in mouse cells. One of the potential mechanisms underlying the difference between mouse and human cells is the difference in the stringency of the regulation of CDK2/cyclin E activation: In mouse cells, CDK2/ cyclin E activation is observed rather promiscuously around mid-late G1. In contrast, in human cells, activation of CDK2/cyclin E is strictly controlled, only occurring during a very narrow window in late G1 (Ekholm et al., 2001) . In support of this idea, constitutive activation of CDK2/cyclin E has been shown to synergistically induce centrosome hyperamplification with p53 inactivation (Mussman et al., 2000) . Thus it appears that promiscuous activation of CDK2/cyclin E may set a background for induction of centrosome hyperamplification by loss of p53. We are currently examining this possibility. Figure 5 p53 controls centrosome duplication through multiple pathways in a transactivation-dependent and -independent manners. p53 controls both initiation of centrosome duplication and suppression of re-duplication in a transactivation-dependent manner via up-regulating p21, and in a transactivation-independent manner potentially via direct physical association with centrosomes
